CHICAGO--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced results from the primary analysis of an international, randomized Phase 3 study that showed treatment with a VELCADE® (bortezomib)-based combination therapy demonstrated a 59 percent relative improvement in the study’s primary endpoint of progression-free survival (24.7 vs. 14.4 months; Hazard Ratio [HR] 0.63; P<0.001) among previously untreated patients with mantle cell lymphoma (MCL) compared to treatment with a standard therapy. These data were presented today at the annual meeting of the American Society of Clinical Oncology (ASCO).
Help employers find you! Check out all the jobs and post your resume.
